CC
FULC icon

Centiva Capital’s Fulcrum Therapeutics FULC Stock Holding History

Centiva Capital’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-76,577
Closed -$273K – 1924
2024
Q3 		$273K Buy
+76,577
New +$568K 0.01% 1634
2024
Q2 		– Sell
-43,080
Closed -$407K – 2218
2024
Q1 		$407K Buy
+43,080
New +$385K 0.01% 1096
2023
Q4 		– Sell
-10,747
Closed -$47.7K – 1953
2023
Q3 		$47.7K Buy
+10,747
New +$47K ﹤0.01% 1606

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Centiva Capital's FULC Position: Q4 2024 in Review

Centiva Capital sold out of Fulcrum Therapeutics (FULC) in Q4 2024, closing a stake of 76,577 shares — an estimated $273K sold.

Centiva Capital first reported a position in FULC in Q3 2023 and held it in 3 quarters. The position peaked at $407K in Q1 2024. 119 funds tracked by Wall St. Rank hold FULC as of Q4 2024.

  • Centiva Capital reported no remaining Fulcrum Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Centiva Capital sold 76,577 Fulcrum Therapeutics shares in Q4 2024, an estimated $273K.
  • Centiva Capital first reported a position in Fulcrum Therapeutics in Q3 2023 and held it in 3 quarters.
  • Centiva Capital's Fulcrum Therapeutics position peaked at $407K in Q1 2024.
  • 119 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2024.

Based on Centiva Capital's 13F filing for Q4 2024, filed 14 Feb 2025.